Back to Search
DENNIS BRUEMMER, MD PHD
MD PHD
Cardiovascular Disease Physician
NPI: 1487661526IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
35.136326(OH)
CMS Specialties
PrimaryCARDIOVASCULAR DISEASE (CARDIOLOGY)
Education
OTHER
Class of 1998
Research & Publications (20)
Deficiency of the NR4A neuron-derived orphan receptor-1 attenuates neointima formation after vascular injury.
PMID 19153266·Circulation·2009
7-preclinical
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
PMID 19597507·Nat Chem Biol·2009
7-preclinical
The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation.
PMID 18818403·Circ Res·2008
7-preclinical
Liver X receptors as therapeutic targets in metabolism and atherosclerosis.
PMID 18366990·Curr Atheroscler Rep·2008
6-review
Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-gamma: Therapeutic Implications for Cardiovascular Diseases.
PMID 18288288·PPAR Res·2008
8-other
Phosphorylated troglitazone activates PPARgamma and inhibits vascular smooth muscle cell proliferation and proteoglycan synthesis.
PMID 18356692·J Cardiovasc Pharmacol·2008
7-preclinical
Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice.
PMID 17823662·J Clin Invest·2007
7-preclinical
Zinc deficiency alters lipid metabolism in LDL receptor deficient mice treated with rosiglitazone.
PMID 17951467·J Nutr·2007
7-preclinical
PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.
PMID 17360982·Diabetes·2007
7-preclinical
C-Peptide in insulin resistance and vascular complications: teaching an old dog new tricks.
PMID 17122442·Circ Res·2006
6-review
Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells.
PMID 16556873·Circ Res·2006
7-preclinical
Osteopontin deficiency protects mice from Dextran sodium sulfate-induced colitis.
PMID 16917234·Inflamm Bowel Dis·2006
7-preclinical
The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation.
PMID 16945922·J Biol Chem·2006
7-preclinical
Transcriptional repression of ATP-binding cassette transporter A1 gene in macrophages: a novel atherosclerotic effect of angiotensin II.
PMID 16224068·Circ Res·2005
7-preclinical
Liver x receptors: potential novel targets in cardiovascular diseases.
PMID 16503873·Curr Drug Targets Cardiovasc Haematol Disord·2005
6-review
New targets for PPARgamma in the vessel wall: implications for restenosis.
PMID 15711579·Int J Obes (Lond)·2005
6-review
Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways.
PMID 15790955·Circ Res·2005
7-preclinical
Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation.
PMID 15992368·J Neurochem·2005
7-preclinical
Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting?
PMID 15470905·Clin Cardiol·2004
6-review
Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries.
PMID 15539633·Circ Res·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 9500 EUCLID AVE
CLEVELAND, OH 44195 - Phone
- (216) 444-6697
Quick Facts
- NPI
- 1487661526
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 28
- Publications
- 20
Are you this provider?
Claim Your Profile